| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 116 | 2024 | 3218 | 8.970 |
Why?
|
| Kidney Neoplasms | 109 | 2024 | 4312 | 7.430 |
Why?
|
| Carbonic Anhydrases | 9 | 2024 | 109 | 2.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 12 | 2024 | 307 | 1.270 |
Why?
|
| Prostate | 16 | 2022 | 1793 | 1.240 |
Why?
|
| Tumor Suppressor Proteins | 23 | 2021 | 2802 | 1.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 14 | 2024 | 1088 | 1.150 |
Why?
|
| Antigens, Neoplasm | 11 | 2024 | 1998 | 1.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 11 | 2022 | 1139 | 0.940 |
Why?
|
| Endogenous Retroviruses | 2 | 2023 | 111 | 0.880 |
Why?
|
| Prostatic Neoplasms | 33 | 2024 | 11345 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 36 | 2024 | 8515 | 0.790 |
Why?
|
| Urologic Neoplasms | 5 | 2019 | 320 | 0.760 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2022 | 5643 | 0.710 |
Why?
|
| Trans-Activators | 9 | 2015 | 2860 | 0.700 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2023 | 421 | 0.680 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2019 | 800 | 0.640 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2017 | 621 | 0.630 |
Why?
|
| Mutation | 31 | 2022 | 29932 | 0.600 |
Why?
|
| PTEN Phosphohydrolase | 18 | 2022 | 1115 | 0.600 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 6 | 2024 | 81 | 0.590 |
Why?
|
| Interleukin-2 | 6 | 2016 | 1889 | 0.580 |
Why?
|
| Anilides | 4 | 2022 | 409 | 0.560 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 638 | 0.560 |
Why?
|
| Niacinamide | 8 | 2017 | 414 | 0.550 |
Why?
|
| Prognosis | 34 | 2024 | 29658 | 0.550 |
Why?
|
| Neoplasm Metastasis | 20 | 2019 | 4902 | 0.550 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2020 | 2058 | 0.540 |
Why?
|
| Pyridines | 11 | 2022 | 2879 | 0.540 |
Why?
|
| Immunohistochemistry | 32 | 2021 | 11071 | 0.540 |
Why?
|
| Nephrectomy | 6 | 2024 | 1016 | 0.540 |
Why?
|
| Stem Cells | 7 | 2015 | 3523 | 0.530 |
Why?
|
| Phosphoproteins | 6 | 2013 | 2440 | 0.530 |
Why?
|
| Phenylurea Compounds | 8 | 2017 | 529 | 0.510 |
Why?
|
| Cell Proliferation | 20 | 2024 | 10446 | 0.500 |
Why?
|
| Genes, Tumor Suppressor | 12 | 2021 | 1055 | 0.490 |
Why?
|
| Benzenesulfonates | 6 | 2011 | 165 | 0.490 |
Why?
|
| Cell Line, Tumor | 43 | 2024 | 16939 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2022 | 2919 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 11712 | 0.470 |
Why?
|
| Antineoplastic Agents | 21 | 2020 | 13630 | 0.460 |
Why?
|
| Ubiquitin Thiolesterase | 5 | 2021 | 454 | 0.450 |
Why?
|
| Transcription Factors | 24 | 2023 | 12103 | 0.440 |
Why?
|
| Humans | 212 | 2024 | 760621 | 0.440 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2017 | 2276 | 0.430 |
Why?
|
| Gene Dosage | 5 | 2014 | 1218 | 0.420 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 785 | 0.420 |
Why?
|
| Gene Expression Profiling | 20 | 2021 | 9411 | 0.410 |
Why?
|
| Immunotherapy | 11 | 2024 | 4642 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1347 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2020 | 567 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 8 | 2024 | 319 | 0.390 |
Why?
|
| Mice | 74 | 2024 | 81208 | 0.390 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2016 | 2049 | 0.390 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3610 | 0.380 |
Why?
|
| Nuclear Proteins | 8 | 2020 | 5791 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 12 | 2021 | 2828 | 0.370 |
Why?
|
| Indans | 3 | 2022 | 91 | 0.370 |
Why?
|
| Sulfonamides | 5 | 2017 | 1977 | 0.360 |
Why?
|
| DNA-Binding Proteins | 20 | 2021 | 9585 | 0.340 |
Why?
|
| Immunoenzyme Techniques | 7 | 2015 | 1705 | 0.330 |
Why?
|
| Animals | 90 | 2024 | 167963 | 0.330 |
Why?
|
| Male | 108 | 2024 | 359744 | 0.330 |
Why?
|
| Cell Lineage | 3 | 2013 | 2533 | 0.330 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 4550 | 0.330 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2010 | 148 | 0.330 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2009 | 151 | 0.320 |
Why?
|
| Receptors, KIR | 2 | 2020 | 113 | 0.310 |
Why?
|
| Sulfones | 3 | 2022 | 447 | 0.310 |
Why?
|
| Pyrimidines | 7 | 2022 | 3016 | 0.310 |
Why?
|
| Histone Demethylases | 6 | 2023 | 323 | 0.310 |
Why?
|
| Histocytochemistry | 4 | 2024 | 700 | 0.310 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2012 | 507 | 0.300 |
Why?
|
| Tumor Microenvironment | 9 | 2024 | 3844 | 0.290 |
Why?
|
| Neoplasm Staging | 12 | 2024 | 11152 | 0.290 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 18137 | 0.290 |
Why?
|
| Cell Differentiation | 11 | 2024 | 11481 | 0.290 |
Why?
|
| Signal Transduction | 26 | 2021 | 23376 | 0.280 |
Why?
|
| Female | 92 | 2024 | 391270 | 0.270 |
Why?
|
| Urothelium | 3 | 2016 | 277 | 0.270 |
Why?
|
| Adenoma | 3 | 2015 | 2148 | 0.270 |
Why?
|
| Pyrroles | 6 | 2017 | 1137 | 0.260 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 10181 | 0.260 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 2053 | 0.260 |
Why?
|
| Indazoles | 6 | 2024 | 302 | 0.260 |
Why?
|
| Androgens | 5 | 2013 | 1291 | 0.250 |
Why?
|
| Retinoblastoma Protein | 3 | 2018 | 670 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 9 | 2024 | 2803 | 0.250 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 377 | 0.240 |
Why?
|
| Epigenomics | 4 | 2024 | 936 | 0.240 |
Why?
|
| Cell Cycle Proteins | 7 | 2012 | 3446 | 0.240 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2016 | 666 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2864 | 0.240 |
Why?
|
| Lipogenesis | 2 | 2018 | 210 | 0.230 |
Why?
|
| Indoles | 6 | 2017 | 1829 | 0.230 |
Why?
|
| Epithelial Cells | 10 | 2009 | 3663 | 0.230 |
Why?
|
| Aged | 49 | 2024 | 169152 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 1347 | 0.230 |
Why?
|
| Membrane Proteins | 5 | 2014 | 7850 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6544 | 0.220 |
Why?
|
| Middle Aged | 52 | 2024 | 220352 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2018 | 1889 | 0.220 |
Why?
|
| Sirolimus | 6 | 2018 | 1547 | 0.220 |
Why?
|
| Adenocarcinoma | 10 | 2022 | 6315 | 0.220 |
Why?
|
| Mice, Nude | 13 | 2019 | 3607 | 0.210 |
Why?
|
| Butyrate Response Factor 1 | 1 | 2022 | 10 | 0.210 |
Why?
|
| Neoplasms | 12 | 2024 | 22072 | 0.210 |
Why?
|
| Survival Analysis | 9 | 2021 | 10182 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2018 | 5253 | 0.210 |
Why?
|
| Tankyrases | 1 | 2022 | 13 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 938 | 0.210 |
Why?
|
| Carcinoma | 4 | 2023 | 2331 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 861 | 0.200 |
Why?
|
| Survival Rate | 9 | 2020 | 12808 | 0.200 |
Why?
|
| DNA, Neoplasm | 4 | 2016 | 1745 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2023 | 3484 | 0.190 |
Why?
|
| Apoptosis | 13 | 2019 | 9501 | 0.190 |
Why?
|
| Treatment Outcome | 24 | 2024 | 65017 | 0.190 |
Why?
|
| Loss of Heterozygosity | 2 | 2021 | 659 | 0.190 |
Why?
|
| Receptor, Notch2 | 1 | 2021 | 87 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2019 | 3584 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2016 | 2448 | 0.190 |
Why?
|
| Immunoglobulins | 2 | 2023 | 859 | 0.190 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 58995 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 8 | 2013 | 6068 | 0.190 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2021 | 158 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 698 | 0.190 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2022 | 317 | 0.190 |
Why?
|
| Immune System Diseases | 1 | 2023 | 258 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2014 | 600 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 9276 | 0.180 |
Why?
|
| Sarcoma | 3 | 2023 | 1786 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2024 | 375 | 0.180 |
Why?
|
| Doxorubicin | 5 | 2014 | 2209 | 0.180 |
Why?
|
| Catheter Ablation | 7 | 2011 | 2758 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 412 | 0.180 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2000 | 330 | 0.180 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2019 | 174 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2000 | 345 | 0.180 |
Why?
|
| Epithelium | 3 | 2015 | 1605 | 0.170 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2019 | 30 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 3529 | 0.170 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1999 | 91 | 0.170 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 259 | 0.170 |
Why?
|
| Genome, Human | 5 | 2018 | 4417 | 0.170 |
Why?
|
| Amino Acid Transport System y+ | 2 | 2016 | 37 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2020 | 544 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 161 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 2640 | 0.170 |
Why?
|
| Aspartic Acid | 1 | 2002 | 576 | 0.170 |
Why?
|
| Lung Neoplasms | 6 | 2023 | 13262 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2022 | 1596 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2013 | 4024 | 0.160 |
Why?
|
| Neuroendocrine Cells | 1 | 2019 | 62 | 0.160 |
Why?
|
| Disease-Free Survival | 8 | 2017 | 6828 | 0.160 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 285 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 495 | 0.160 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 210 | 0.160 |
Why?
|
| Serine Proteases | 1 | 2018 | 50 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 3 | 2000 | 935 | 0.160 |
Why?
|
| Cell Cycle | 6 | 2014 | 2934 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 877 | 0.160 |
Why?
|
| Ubiquitination | 2 | 2014 | 1008 | 0.160 |
Why?
|
| Triazines | 1 | 2020 | 310 | 0.150 |
Why?
|
| DNA Mutational Analysis | 3 | 2013 | 4107 | 0.150 |
Why?
|
| Oncogenes | 4 | 2023 | 1220 | 0.150 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 2013 | 0.150 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2018 | 25 | 0.150 |
Why?
|
| RNA, Neoplasm | 3 | 2015 | 749 | 0.150 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.150 |
Why?
|
| Pattern Recognition, Automated | 1 | 2024 | 994 | 0.150 |
Why?
|
| Gene Rearrangement | 5 | 2011 | 1122 | 0.150 |
Why?
|
| Glutathione Peroxidase | 1 | 2019 | 256 | 0.150 |
Why?
|
| Foot Diseases | 1 | 1999 | 147 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2019 | 556 | 0.150 |
Why?
|
| Phosphorylation | 9 | 2016 | 8313 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 1152 | 0.150 |
Why?
|
| Adult | 33 | 2024 | 219994 | 0.150 |
Why?
|
| Kidney | 7 | 2019 | 7064 | 0.150 |
Why?
|
| Phenotype | 14 | 2023 | 16546 | 0.140 |
Why?
|
| Chromatin | 3 | 2023 | 2938 | 0.140 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 21025 | 0.140 |
Why?
|
| Histone Code | 1 | 2018 | 156 | 0.140 |
Why?
|
| Protein Kinases | 4 | 2015 | 1612 | 0.140 |
Why?
|
| Liposomes | 2 | 2011 | 777 | 0.140 |
Why?
|
| Disease Progression | 12 | 2024 | 13502 | 0.140 |
Why?
|
| Nevus, Pigmented | 1 | 1999 | 221 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2020 | 678 | 0.140 |
Why?
|
| Genomics | 8 | 2022 | 5794 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 346 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 2210 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2018 | 789 | 0.130 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 65 | 0.130 |
Why?
|
| Eccrine Glands | 1 | 1996 | 52 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 6853 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 786 | 0.130 |
Why?
|
| Receptor, erbB-2 | 3 | 2012 | 2554 | 0.130 |
Why?
|
| Spin Labels | 3 | 2016 | 336 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 4 | 2024 | 1612 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2021 | 3616 | 0.130 |
Why?
|
| Cell Membrane | 2 | 2015 | 3682 | 0.130 |
Why?
|
| Activin Receptors, Type II | 1 | 2016 | 124 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2015 | 376 | 0.130 |
Why?
|
| Mice, Transgenic | 10 | 2013 | 9530 | 0.130 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 137 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1056 | 0.130 |
Why?
|
| Mice, Knockout | 11 | 2021 | 14372 | 0.130 |
Why?
|
| Enzyme Inhibitors | 6 | 2022 | 3726 | 0.130 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 8986 | 0.120 |
Why?
|
| Neoplasm Transplantation | 7 | 2014 | 2014 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 39261 | 0.120 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 310 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 454 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1147 | 0.120 |
Why?
|
| Angiomyolipoma | 1 | 2016 | 184 | 0.120 |
Why?
|
| Metaplasia | 2 | 2013 | 320 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2019 | 743 | 0.120 |
Why?
|
| Skin Neoplasms | 5 | 2004 | 5799 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 436 | 0.120 |
Why?
|
| Paracrine Communication | 1 | 2016 | 277 | 0.120 |
Why?
|
| src-Family Kinases | 2 | 2014 | 535 | 0.120 |
Why?
|
| Proline | 1 | 2016 | 457 | 0.120 |
Why?
|
| Imidazoles | 4 | 2017 | 1180 | 0.120 |
Why?
|
| Paraffin Embedding | 3 | 2008 | 302 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 1454 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 9185 | 0.120 |
Why?
|
| Elafin | 1 | 2014 | 31 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2014 | 63 | 0.120 |
Why?
|
| Pyrazines | 1 | 2020 | 1199 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2016 | 203 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2017 | 873 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 106 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 1722 | 0.120 |
Why?
|
| Leukemia | 1 | 2022 | 1520 | 0.110 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2012 | 123 | 0.110 |
Why?
|
| Enzyme Activators | 1 | 2014 | 57 | 0.110 |
Why?
|
| Immunity | 2 | 2018 | 998 | 0.110 |
Why?
|
| Cytological Techniques | 1 | 2015 | 218 | 0.110 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 215 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2015 | 311 | 0.110 |
Why?
|
| Protein Isoforms | 3 | 2014 | 1697 | 0.110 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 23 | 0.110 |
Why?
|
| Retrospective Studies | 11 | 2024 | 80372 | 0.110 |
Why?
|
| Hand | 1 | 1999 | 903 | 0.110 |
Why?
|
| Myeloid Cells | 3 | 2023 | 820 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2019 | 193 | 0.110 |
Why?
|
| Models, Biological | 9 | 2016 | 9467 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2016 | 559 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1440 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 2895 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1388 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 126 | 0.110 |
Why?
|
| Pituitary Neoplasms | 2 | 2018 | 1313 | 0.110 |
Why?
|
| Cystectomy | 2 | 2017 | 697 | 0.100 |
Why?
|
| Cyclin D | 1 | 2012 | 72 | 0.100 |
Why?
|
| Brain Injuries | 2 | 2002 | 2044 | 0.100 |
Why?
|
| Sphingosine | 1 | 2015 | 308 | 0.100 |
Why?
|
| Genotype | 7 | 2018 | 12960 | 0.100 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 145 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2011 | 4490 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2019 | 9716 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2015 | 339 | 0.100 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2018 | 781 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 10344 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 385 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 112 | 0.100 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 796 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 473 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 428 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2015 | 3800 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 230 | 0.100 |
Why?
|
| Cyclins | 1 | 2014 | 593 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 4713 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2011 | 12 | 0.100 |
Why?
|
| Qb-SNARE Proteins | 1 | 2011 | 34 | 0.100 |
Why?
|
| Receptors, Androgen | 4 | 2006 | 1077 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 442 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2001 | 1077 | 0.100 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 419 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1588 | 0.100 |
Why?
|
| Cytoplasm | 3 | 2014 | 1516 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2020 | 41335 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2011 | 397 | 0.100 |
Why?
|
| Cysteine | 1 | 2016 | 895 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 2418 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 629 | 0.090 |
Why?
|
| Cisplatin | 2 | 2014 | 1644 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1648 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2019 | 1037 | 0.090 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2011 | 152 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3618 | 0.090 |
Why?
|
| Cullin Proteins | 1 | 2012 | 178 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 370 | 0.090 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 1837 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2012 | 2379 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 6 | 2018 | 6131 | 0.090 |
Why?
|
| Androgen Antagonists | 3 | 2022 | 1442 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 286 | 0.090 |
Why?
|
| Biopsy | 3 | 2019 | 6771 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 2526 | 0.090 |
Why?
|
| Myocardial Stunning | 1 | 2010 | 66 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2010 | 81 | 0.090 |
Why?
|
| Quercetin | 1 | 2011 | 97 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 508 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2012 | 202 | 0.090 |
Why?
|
| Neoplasms, Experimental | 2 | 2006 | 1229 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 599 | 0.090 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2011 | 257 | 0.090 |
Why?
|
| HEK293 Cells | 5 | 2019 | 4264 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2011 | 234 | 0.090 |
Why?
|
| Metabolomics | 1 | 2019 | 1628 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 3075 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 2782 | 0.090 |
Why?
|
| Mice, SCID | 2 | 2014 | 2627 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 191 | 0.090 |
Why?
|
| DNA Methylation | 4 | 2024 | 4373 | 0.080 |
Why?
|
| Myristic Acids | 1 | 2009 | 49 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 2821 | 0.080 |
Why?
|
| Rats, Inbred F344 | 5 | 2010 | 825 | 0.080 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 724 | 0.080 |
Why?
|
| Gene Deletion | 5 | 2020 | 2668 | 0.080 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 50 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 225 | 0.080 |
Why?
|
| Epigenesis, Genetic | 3 | 2024 | 3758 | 0.080 |
Why?
|
| Oxygen | 2 | 2019 | 4193 | 0.080 |
Why?
|
| Computational Biology | 1 | 2021 | 3505 | 0.080 |
Why?
|
| Leiomyomatosis | 1 | 2009 | 69 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.080 |
Why?
|
| Down-Regulation | 4 | 2015 | 2913 | 0.080 |
Why?
|
| Brain Edema | 2 | 2006 | 603 | 0.080 |
Why?
|
| Quinolines | 2 | 2012 | 759 | 0.080 |
Why?
|
| STAT5 Transcription Factor | 1 | 2009 | 264 | 0.080 |
Why?
|
| Gene Expression | 2 | 2019 | 7588 | 0.080 |
Why?
|
| Aminopyridines | 3 | 2019 | 564 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 2018 | 3602 | 0.080 |
Why?
|
| Oncogene Protein p21(ras) | 2 | 2014 | 68 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1810 | 0.080 |
Why?
|
| Immunophenotyping | 2 | 2011 | 1871 | 0.070 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 658 | 0.070 |
Why?
|
| Up-Regulation | 5 | 2016 | 4122 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2022 | 1999 | 0.070 |
Why?
|
| RNA, Messenger | 8 | 2016 | 12766 | 0.070 |
Why?
|
| Skin Diseases | 1 | 1996 | 1089 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 22023 | 0.070 |
Why?
|
| Tissue Banks | 1 | 2008 | 184 | 0.070 |
Why?
|
| Glioma | 1 | 2022 | 3420 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 2717 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1246 | 0.070 |
Why?
|
| DNA Damage | 2 | 2015 | 2442 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2011 | 511 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2015 | 2611 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 2506 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2536 | 0.070 |
Why?
|
| Keratin-15 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 2 | 2000 | 305 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1613 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 1602 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2006 | 57 | 0.070 |
Why?
|
| Combined Modality Therapy | 7 | 2019 | 8552 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 5785 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2022 | 2981 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2022 | 3426 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2005 | 104 | 0.070 |
Why?
|
| Rats | 11 | 2013 | 23711 | 0.070 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 575 | 0.070 |
Why?
|
| Cell Survival | 3 | 2014 | 5797 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 15789 | 0.070 |
Why?
|
| Arsenicals | 1 | 2006 | 117 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2009 | 1513 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2010 | 1736 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 995 | 0.060 |
Why?
|
| Quality Control | 1 | 2008 | 828 | 0.060 |
Why?
|
| Genetic Variation | 3 | 2016 | 6551 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 3 | 2020 | 2005 | 0.060 |
Why?
|
| Ki-67 Antigen | 4 | 2016 | 631 | 0.060 |
Why?
|
| Sarcoma, Experimental | 1 | 2005 | 117 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 780 | 0.060 |
Why?
|
| Melanoma | 2 | 2019 | 5697 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1343 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 1895 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 8056 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 378 | 0.060 |
Why?
|
| Arginase | 1 | 2005 | 80 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 11903 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 2414 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2012 | 4938 | 0.060 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 7593 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2332 | 0.060 |
Why?
|
| In Situ Hybridization | 4 | 2001 | 1900 | 0.060 |
Why?
|
| Oxides | 1 | 2006 | 401 | 0.060 |
Why?
|
| Histones | 4 | 2019 | 2583 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 819 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2002 | 1204 | 0.060 |
Why?
|
| Retroviridae | 2 | 2008 | 850 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2009 | 707 | 0.060 |
Why?
|
| Cell Line | 5 | 2019 | 15620 | 0.060 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 2203 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2008 | 619 | 0.060 |
Why?
|
| Trauma Severity Indices | 1 | 2006 | 478 | 0.060 |
Why?
|
| Time Factors | 6 | 2017 | 40165 | 0.060 |
Why?
|
| Reference Values | 2 | 2002 | 4925 | 0.060 |
Why?
|
| Blotting, Western | 7 | 2010 | 5039 | 0.060 |
Why?
|
| Morpholines | 3 | 2016 | 583 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2001 | 656 | 0.060 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 2000 | 40 | 0.060 |
Why?
|
| Epidermal Growth Factor | 2 | 2008 | 695 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 412 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 854 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 459 | 0.050 |
Why?
|
| MicroRNAs | 3 | 2015 | 3790 | 0.050 |
Why?
|
| Salicylanilides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15289 | 0.050 |
Why?
|
| Methylation | 2 | 2019 | 1082 | 0.050 |
Why?
|
| Prospective Studies | 8 | 2022 | 54303 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 595 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 3 | 2013 | 1617 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2002 | 713 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2006 | 792 | 0.050 |
Why?
|
| Antibodies | 2 | 2024 | 2421 | 0.050 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2002 | 59 | 0.050 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2002 | 90 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 177 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3735 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2013 | 4000 | 0.050 |
Why?
|
| Orchiectomy | 3 | 2013 | 470 | 0.050 |
Why?
|
| Transfection | 4 | 2021 | 5781 | 0.050 |
Why?
|
| Neurochemistry | 1 | 2002 | 29 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2009 | 3615 | 0.050 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 17 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 84 | 0.050 |
Why?
|
| Dissection | 2 | 2002 | 298 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 3387 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 895 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2010 | 1085 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2024 | 586 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2520 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 1657 | 0.050 |
Why?
|
| Carcinoma, Embryonal | 1 | 2001 | 37 | 0.050 |
Why?
|
| Phenylthiohydantoin | 2 | 2013 | 204 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2002 | 100 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1630 | 0.050 |
Why?
|
| Species Specificity | 2 | 2019 | 2418 | 0.050 |
Why?
|
| Conserved Sequence | 2 | 2015 | 1167 | 0.050 |
Why?
|
| Benzimidazoles | 2 | 2019 | 858 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 6538 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 491 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 586 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2021 | 56 | 0.050 |
Why?
|
| Neutrophils | 3 | 2019 | 3767 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2022 | 89 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4899 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 487 | 0.050 |
Why?
|
| Cell Death | 2 | 2010 | 1672 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 1841 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 1791 | 0.050 |
Why?
|
| Cyclin D1 | 2 | 2014 | 451 | 0.050 |
Why?
|
| Isoenzymes | 3 | 2014 | 1690 | 0.050 |
Why?
|
| Insulin | 2 | 2008 | 6597 | 0.050 |
Why?
|
| cdc25 Phosphatases | 1 | 2000 | 60 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2001 | 168 | 0.040 |
Why?
|
| Vinblastine | 2 | 2014 | 487 | 0.040 |
Why?
|
| Cell Division | 3 | 2002 | 4463 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2008 | 3094 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 110 | 0.040 |
Why?
|
| Pseudolymphoma | 1 | 2000 | 30 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 1008 | 0.040 |
Why?
|
| Young Adult | 5 | 2020 | 58741 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2004 | 772 | 0.040 |
Why?
|
| Seminoma | 1 | 2001 | 134 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1157 | 0.040 |
Why?
|
| Benzamides | 3 | 2013 | 1369 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 2 | 2001 | 255 | 0.040 |
Why?
|
| Fibroblasts | 4 | 2018 | 4090 | 0.040 |
Why?
|
| Choline | 1 | 2002 | 513 | 0.040 |
Why?
|
| Retreatment | 1 | 2021 | 600 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 551 | 0.040 |
Why?
|
| Microvessels | 2 | 2015 | 572 | 0.040 |
Why?
|
| Cell Nucleus | 4 | 2000 | 2907 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2020 | 2471 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 361 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 17790 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 373 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 468 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 139 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
| Macrophages | 3 | 2021 | 5745 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2015 | 1089 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 217 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 1999 | 119 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2006 | 4573 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 17624 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 12626 | 0.040 |
Why?
|
| Proteins | 2 | 2010 | 6029 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3775 | 0.040 |
Why?
|
| Heterozygote | 2 | 2021 | 2798 | 0.040 |
Why?
|
| Canada | 1 | 2024 | 2128 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2000 | 412 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 325 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2000 | 431 | 0.040 |
Why?
|
| DNA Primers | 2 | 2000 | 2819 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1764 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 168 | 0.040 |
Why?
|
| Risk Factors | 8 | 2022 | 74359 | 0.040 |
Why?
|
| Ligands | 2 | 2016 | 3276 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1999 | 241 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 558 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 14660 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 534 | 0.040 |
Why?
|
| Alleles | 3 | 2018 | 6898 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 271 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2698 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 1763 | 0.040 |
Why?
|
| Mice, Mutant Strains | 3 | 2010 | 1753 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 125 | 0.040 |
Why?
|
| Nitriles | 2 | 2013 | 956 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 849 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 1313 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2221 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1407 | 0.040 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 12965 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 479 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 10827 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2018 | 233 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 92 | 0.040 |
Why?
|
| Protein Binding | 3 | 2015 | 9335 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1999 | 736 | 0.040 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.040 |
Why?
|
| Transcriptional Activation | 3 | 2010 | 1755 | 0.040 |
Why?
|
| RNA Interference | 2 | 2019 | 2846 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3707 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 36290 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 191 | 0.030 |
Why?
|
| Triazoles | 1 | 2022 | 904 | 0.030 |
Why?
|
| Melanins | 1 | 1999 | 291 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2016 | 137 | 0.030 |
Why?
|
| Testosterone | 2 | 2012 | 2470 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2020 | 1578 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1343 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2010 | 6238 | 0.030 |
Why?
|
| Glucose | 1 | 2008 | 4351 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 6216 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2023 | 1268 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 929 | 0.030 |
Why?
|
| Clone Cells | 1 | 1999 | 1660 | 0.030 |
Why?
|
| Creatinine | 1 | 2002 | 1903 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 42 | 0.030 |
Why?
|
| Benzylamines | 1 | 2017 | 248 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 802 | 0.030 |
Why?
|
| Erythema | 1 | 1997 | 262 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 247 | 0.030 |
Why?
|
| Binding Sites | 2 | 2015 | 6048 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 1446 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 162 | 0.030 |
Why?
|
| Integrases | 1 | 2018 | 516 | 0.030 |
Why?
|
| Melanocytes | 1 | 1999 | 512 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1387 | 0.030 |
Why?
|
| Perfusion | 2 | 2011 | 1376 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 12446 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 955 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2002 | 942 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 2651 | 0.030 |
Why?
|
| Chimera | 1 | 2016 | 453 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2014 | 15 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2001 | 2194 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3527 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 801 | 0.030 |
Why?
|
| Germ Cells | 1 | 2018 | 635 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 276 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2020 | 854 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2015 | 111 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 1006 | 0.030 |
Why?
|
| Immunity, Innate | 2 | 2017 | 3047 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 2943 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 245 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 280 | 0.030 |
Why?
|
| Multigene Family | 2 | 2010 | 1077 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 371 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 13451 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 255 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 303 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 1998 | 490 | 0.030 |
Why?
|
| Multiprotein Complexes | 2 | 2010 | 1120 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2014 | 189 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 653 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 3025 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 301 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 963 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 1894 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 402 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 630 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 2013 | 225 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2000 | 1019 | 0.030 |
Why?
|
| Liver | 2 | 2008 | 7509 | 0.030 |
Why?
|
| Cell Communication | 2 | 2012 | 1653 | 0.030 |
Why?
|
| RNA | 3 | 2014 | 2722 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2014 | 195 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2013 | 202 | 0.030 |
Why?
|
| RNA, Small Interfering | 3 | 2009 | 3442 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3568 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 389 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1996 | 1155 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 153 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 87810 | 0.030 |
Why?
|
| Breast | 1 | 2002 | 1963 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1296 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 727 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 801 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2001 | 649 | 0.030 |
Why?
|
| Piperazines | 2 | 2019 | 2525 | 0.030 |
Why?
|
| beta Catenin | 2 | 2011 | 1043 | 0.030 |
Why?
|
| Research Design | 1 | 2008 | 6180 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2014 | 257 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 551 | 0.030 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 45 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 1375 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2009 | 1649 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 12293 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2009 | 1173 | 0.020 |
Why?
|
| Mesothelioma | 1 | 1998 | 807 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 635 | 0.020 |
Why?
|
| Cyclin E | 1 | 2012 | 155 | 0.020 |
Why?
|
| Glomus Tumor | 1 | 2012 | 62 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 726 | 0.020 |
Why?
|
| Lymphoma | 1 | 2001 | 1898 | 0.020 |
Why?
|
| Exons | 2 | 2011 | 2388 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2015 | 541 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2011 | 41 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2313 | 0.020 |
Why?
|
| Keratins | 2 | 2003 | 497 | 0.020 |
Why?
|
| Endonucleases | 1 | 2014 | 370 | 0.020 |
Why?
|
| Homozygote | 1 | 2016 | 1788 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 256 | 0.020 |
Why?
|
| CpG Islands | 1 | 2015 | 1221 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 798 | 0.020 |
Why?
|
| Genes, ras | 2 | 2004 | 655 | 0.020 |
Why?
|
| Endocytosis | 1 | 2015 | 959 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2017 | 1166 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 321 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2016 | 1167 | 0.020 |
Why?
|
| New York | 1 | 2013 | 875 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2016 | 1368 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1786 | 0.020 |
Why?
|
| Myocardium | 2 | 2010 | 4700 | 0.020 |
Why?
|
| Necrosis | 2 | 2005 | 1612 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 1710 | 0.020 |
Why?
|
| Precipitin Tests | 2 | 2001 | 814 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4925 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 18957 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1975 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 20080 | 0.020 |
Why?
|
| California | 1 | 2014 | 1416 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2011 | 751 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2010 | 92 | 0.020 |
Why?
|
| Atrophy | 2 | 2006 | 1627 | 0.020 |
Why?
|
| Subcellular Fractions | 2 | 2002 | 532 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1738 | 0.020 |
Why?
|
| S Phase | 2 | 2000 | 422 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 8950 | 0.020 |
Why?
|
| Rabbits | 2 | 2006 | 4773 | 0.020 |
Why?
|
| Mitochondria | 2 | 2014 | 3600 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 388 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2000 | 2881 | 0.020 |
Why?
|
| Osteopontin | 1 | 2011 | 302 | 0.020 |
Why?
|
| Aldehydes | 1 | 2010 | 170 | 0.020 |
Why?
|
| Genes, myc | 1 | 2010 | 395 | 0.020 |
Why?
|
| Fumarate Hydratase | 1 | 2009 | 52 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 381 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 191 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 162 | 0.020 |
Why?
|
| Incidence | 2 | 2022 | 21392 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 311 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 12531 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7343 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 1431 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 264 | 0.020 |
Why?
|
| Exudates and Transudates | 2 | 1999 | 175 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1189 | 0.020 |
Why?
|
| Sex Factors | 2 | 2014 | 10547 | 0.020 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 4742 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 413 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5125 | 0.020 |
Why?
|
| Telomerase | 2 | 2004 | 746 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 507 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 496 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2008 | 89 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 1674 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 532 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 731 | 0.020 |
Why?
|
| Algorithms | 1 | 2008 | 13981 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1719 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2013 | 933 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 2176 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2648 | 0.020 |
Why?
|
| Quality of Life | 2 | 2019 | 13308 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 795 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 3969 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5201 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1996 | 3380 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1381 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 1741 | 0.020 |
Why?
|
| Virginia | 1 | 2006 | 116 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2093 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 239 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2138 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3105 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2006 | 195 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 841 | 0.020 |
Why?
|
| Child | 3 | 2018 | 79806 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 1438 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 384 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 282 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 4981 | 0.020 |
Why?
|
| Ornithine | 1 | 2005 | 79 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2017 | 8035 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2008 | 638 | 0.020 |
Why?
|
| DNA Repair | 1 | 2014 | 2039 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20509 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5870 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2022 | 12914 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2005 | 278 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 616 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2014 | 5434 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2008 | 580 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2009 | 2295 | 0.010 |
Why?
|
| United States | 1 | 2012 | 72461 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 5351 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3486 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 165 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 1553 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2893 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3113 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 1336 | 0.010 |
Why?
|
| Interferons | 1 | 2007 | 705 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5206 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1959 | 0.010 |
Why?
|
| Radiography | 1 | 2014 | 6965 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 534 | 0.010 |
Why?
|
| Age Factors | 2 | 2010 | 18416 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1490 | 0.010 |
Why?
|
| Syndrome | 1 | 2009 | 3280 | 0.010 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2002 | 104 | 0.010 |
Why?
|
| Age of Onset | 1 | 2009 | 3301 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5305 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 283 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 135 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 2852 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 2488 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 788 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 548 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 934 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 2002 | 436 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 522 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 2262 | 0.010 |
Why?
|
| Genes, abl | 1 | 2000 | 69 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1754 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 2529 | 0.010 |
Why?
|
| Flutamide | 1 | 2001 | 95 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2013 | 3905 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 149 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 189 | 0.010 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2000 | 7 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2000 | 343 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 666 | 0.010 |
Why?
|
| Ligases | 1 | 2002 | 332 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 869 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 748 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 183 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 384 | 0.010 |
Why?
|
| Forecasting | 1 | 2009 | 2932 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 2000 | 310 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2001 | 286 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 403 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 12922 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 201 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 652 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 425 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 673 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 839 | 0.010 |
Why?
|
| Linear Models | 1 | 2009 | 5877 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2003 | 1134 | 0.010 |
Why?
|
| Doxycycline | 1 | 2000 | 341 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 927 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 3106 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 368 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2000 | 445 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 952 | 0.010 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2000 | 167 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 1060 | 0.010 |
Why?
|
| Antistreptolysin | 1 | 1997 | 6 | 0.010 |
Why?
|
| Sphenoid Bone | 1 | 1999 | 177 | 0.010 |
Why?
|
| Diffusion | 1 | 2000 | 813 | 0.010 |
Why?
|
| Leg Dermatoses | 1 | 1997 | 20 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2000 | 459 | 0.010 |
Why?
|
| Cadherins | 1 | 2002 | 898 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3306 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1997 | 317 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 1999 | 248 | 0.010 |
Why?
|
| Facial Dermatoses | 1 | 1997 | 85 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1997 | 384 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 2192 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1997 | 234 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 2086 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 182 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1997 | 344 | 0.010 |
Why?
|
| Dermatitis | 1 | 1997 | 200 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5251 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 1720 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 376 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1996 | 553 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3959 | 0.010 |
Why?
|
| Arm | 1 | 1997 | 583 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 553 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2001 | 977 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 5496 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1996 | 437 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 1996 | 959 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 6377 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 1827 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 8469 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 1378 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2873 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1996 | 1600 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1996 | 1577 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 1999 | 2056 | 0.000 |
Why?
|
| Recurrence | 1 | 2000 | 8482 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2009 | 24123 | 0.000 |
Why?
|
| Patient Selection | 1 | 1999 | 4283 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1997 | 1628 | 0.000 |
Why?
|
| Heart Failure | 1 | 2010 | 11847 | 0.000 |
Why?
|
| Swine | 1 | 1996 | 5899 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1996 | 3811 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7408 | 0.000 |
Why?
|
| Infant | 1 | 1997 | 36060 | 0.000 |
Why?
|